Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Queensland Health
Teva
Covington
US Department of Justice
US Army
Fish and Richardson
Argus Health

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022187

« Back to Dashboard

NDA 022187 describes INTELENCE, which is a drug marketed by Janssen R And D and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug. Additional details are available on the INTELENCE profile page.

The generic ingredient in INTELENCE is etravirine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the etravirine profile page.
Summary for 022187
Tradename:INTELENCE
Applicant:Janssen R And D
Ingredient:etravirine
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 022187
Suppliers and Packaging for NDA: 022187
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INTELENCE etravirine TABLET;ORAL 022187 NDA State of Florida DOH Central Pharmacy 53808-0787 N 53808-0787-1
INTELENCE etravirine TABLET;ORAL 022187 NDA Physicians Total Care, Inc. 54868-5864 E 54868-5864-0

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Jan 18, 2008TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 5, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHERANTIRETROVIRALS
Patent:➤ Sign UpPatent Expiration:Nov 5, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
Patent:➤ Sign UpPatent Expiration:Nov 5, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Boehringer Ingelheim
Fuji
Fish and Richardson
Farmers Insurance
Healthtrust
McKesson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.